$1.7M Bet On Glatfelter? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed higher by more than 400 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Glatfelter

• The Trade: Glatfelter Corporation GLT 10% owner Duane Clint Carlson acquired a total 550,000 shares an average price of $3.04. To acquire these shares, it cost around $1.67 million.
• What’s Happening: Glatfelter completed its refinancing plan successfully.
• What Glatfelter Does: Glatfelter Corporation manufactures and sells a variety of paper and fiber products. The company operates through two segments: Composite Fibers and Airlaid Materials.

Athira Pharma

• The Trade: Athira Pharma, Inc. ATHA Director Grant Pickering acquired a total of 25,000 shares at an average price of $2.41. The insider spent around $60.35 thousand to buy those shares.
• What’s Happening: Athira Pharma posted a FY22 loss of $2.53 per share.
• What Athira Pharma Does: Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration.

Check This Out: Top 5 Health Care Stocks That May Collapse

NexImmune

• The Trade: NexImmune, Inc. NEXI Director Sol Barer acquired a total of 400,000 shares at an average price of $0.41. To acquire these shares, it cost around $164.12 thousand.
• What’s Happening: Neximmune reported Q4 and FY22 financial results and issued business updates.
• What NexImmune Does: NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology.

Don’t forget to check out our premarket coverage here